Abstract
Respiratory infections represent the fourth most common cause of all deaths across age groups and countries. Treating these infections appropriately is a clear clinical priority and here we outline the types of therapy that are in current use for some of these infections. It is important that treatments are further improved and the potential of inhaled delivery to fulfil this need is considered. We describe novel methodologies that are being applied for the identification and enumeration of microorganisms in the respiratory tract, and propose that ways of improving therapy may arise from understanding better the etiology of respiratory infection and the impact of inhaled drug therapies. The potential for translational benefits for patients are also discussed.
Original language | English |
---|---|
Pages (from-to) | 301-309 |
Number of pages | 9 |
Journal | JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY |
Volume | 21 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2011 |
Externally published | Yes |
Keywords
- Cystic fibrosis
- COPD
- Pneumonia
- Tuberculosis